Biotricity Inc. (Biotricity) has released its first has released its first Corporate Impact Report– revealing that the company’s remote, clinical-grade diagnostic devices are inducing “better patient outcomes and substantial cost savings” across the nation.  Presenting new data, the report highlights specific examples of Biotricity’s impact on “reforming the healthcare market by bridging the gap between effective remote diagnostics, remote patient monitoring and chronic care management.”

Biotricity Inc. (Biotricity) has signed its second distribution agreement with a top five US medical device distributor for the marketing and distribution of its two cardiac monitoring solutions (CMS) designed for cardiologists’ patient use – Bioflux^® and Biotres^TM.  The distribution agreement covers Bioflux and Biotres and will be distributed directly to hospitals and clinics for professional medical utilization with suitable patients.

Biotricity Inc. (Biotricity) has signed an agreement with a leading group ‎purchasing organization (“GPO”) for national distribution of its cardiac monitoring solutions, Bioflux® and Biotres^TM.  Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO’s are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private ‎clinics, and medical offices that purchase medical devices and supplies at scale.

Biotricity Inc. (Biotricity) today announced that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a new form factor of its Biotres Cardiac Monitoring Device, a three lead device for ECG and arrhythmia monitoring that is intended for lower risk patients.